- Home
- PAVM vs VRAX Comparison
PAVM vs VRAX Comparison
Compare PAVM & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | VRAX |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.1M | 2.1M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PAVM | VRAX |
|---|---|---|
| Price | $2.76 | $2.31 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $36.50 | N/A |
| AVG Volume (30 Days) | 23.8K | ★ 26.3K |
| Earning Date | 11-12-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,000,000.00 | N/A |
| Revenue This Year | $132.39 | N/A |
| Revenue Next Year | $263.64 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.00 | N/A |
| 52 Week Low | $0.21 | $0.10 |
| 52 Week High | $28.44 | $13.19 |
Technical Indicators
Market Signals| Indicator | PAVM | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 35.91 |
| Support Level | N/A | $2.15 |
| Resistance Level | N/A | $3.01 |
| Average True Range (ATR) | 0.00 | 0.18 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 19.05 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.